Recent Updates
Recently added Catalysts

CLBS16

Phase 2

Coronary Microvascular Dysfunction | Biologics | Cardiovascular |Lisata Therapeutics, Inc.|Trials Updated: Jan 8, 2021

CLBS16 development status

Highest phase Phase 2
Registered trials 2 across 1 sponsor since Apr 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

CLBS16 clinical trials

CLBS16 · 1 trial · 1 indication

Phase 2 1
NCT03508609Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery DiseaseCoronary Microvascular Dysfunction
COMPLETED20 Analytics
PHASE2COMPLETED
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Coronary Microvascular DysfunctionUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Coronary Flow Reserve
Day 180

Coronary Flow Reserve (CFR) is a measure of coronary microvascular function.

Secondary Endpoints

Change From Baseline in Microvascular Function as Assessed by Intracoronary Administration of Acetylcholine
Day 180
Change From Baseline in Peripheral Arterial Tonometry
Day 180
Change in Angina Frequency From Baseline
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Autologous CD34 cellsEXPERIMENTALOpen label active treatment arm. Subjects receive autologous CD34 cells.

Interventions

NameTypeDescription
CLBS16BIOLOGICALGCSF-mobilized autologous CD34 cells
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Men or women age ≥18 * History of and currently experiencing angina at least 3 times per week * No obstructive coronary artery disease * On stable medical therapy for 30 days prior to enrollment * Must agree to use a reliable and acceptable method of contraception for the dura...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about CLBS16

What is CLBS16?

CLBS16 is an investigational biologic therapy being developed by Lisata Therapeutics for coronary microvascular dysfunction, a condition affecting the small blood vessels of the heart in patients without obstructive coronary artery disease. It has been studied in a Phase 2 clinical trial conducted in the United States.

What is CLBS16 used for in coronary microvascular dysfunction?

CLBS16 is being developed for coronary microvascular dysfunction, a disorder of the heart's small blood vessels that occurs in patients without obstructive coronary artery disease. Its Phase 2 trial enrolled 20 patients with this condition to evaluate safety and potential bioactivity.

Who makes CLBS16?

CLBS16 is being developed by Lisata Therapeutics, Inc., a company whose shares trade under the ticker LSTA. Lisata is the sponsor of the clinical program evaluating CLBS16 in cardiovascular disease.

What phase is CLBS16 in?

CLBS16 is in Phase 2 clinical development. Its single recorded trial, NCT03508609, was a Phase 2 study that has been completed. CLBS16 is investigational and is not described as an approved therapy.

What clinical trials is CLBS16 in?

CLBS16 has been studied in one clinical trial, NCT03508609, titled Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease. The Phase 2 trial enrolled 20 patients in the United States and is completed.

How was the CLBS16 Phase 2 trial designed?

The CLBS16 Phase 2 trial, NCT03508609, was an uncontrolled study without randomization or double blinding. It enrolled 20 patients aged 18 years and older of all sexes who had coronary microvascular dysfunction and no obstructive coronary artery disease, and it has been completed.